The Lupus Foundation of America and BMJ recently announced the launch and publication of the first scientific research articles in Lupus Science & Medicine™.
The Lupus Foundation of America is funding and leading the development of a first-of-its-kind tool to monitor lupus disease activity called the LFA-REAL™ (Rapid Evaluation of Activity in Lupus) System. LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential to greatly improve medical care and quality of life for people living with this unpredictable and misunderstood autoimmune disease.
The Lupus Foundation of America, in partnership with Eli Lilly and Company and the research firm ICON plc, is conducting an online national research study to better understand the impact of lupus on people with the disease and their caregivers.
The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases.
What a way to kick off 2014! Last night, the House and Senate appropriators dropped the Omnibus Appropriations bill.
Northwestern Medicine® scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease. This is a positive step toward one day developing a vaccine-like therapy that could keep Lupus in remission in the human body without the use of toxic drugs.